{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T05:23:51Z","timestamp":1794288231252,"version":"4.9.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,5,25]],"date-time":"2020-05-25T00:00:00Z","timestamp":1590364800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,25]],"date-time":"2020-05-25T00:00:00Z","timestamp":1590364800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1038\/s41591-020-0880-x","type":"journal-article","created":{"date-parts":[[2020,5,25]],"date-time":"2020-05-25T12:02:35Z","timestamp":1590408155000},"page":"878-885","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":535,"title":["BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial"],"prefix":"10.1038","volume":"26","author":[{"given":"Bruno","family":"Bockorny","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerya","family":"Semenisty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Macarulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erkut","family":"Borazanci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian M.","family":"Wolpin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salomon M.","family":"Stemmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talia","family":"Golan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravit","family":"Geva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitesh J.","family":"Borad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2793-6901","authenticated-orcid":false,"given":"Katrina S.","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6502-2612","authenticated-orcid":false,"given":"Joon Oh","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Abad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Feliu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3240-729X","authenticated-orcid":false,"given":"Mariano","family":"Ponz-Sarvise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amnon","family":"Peled","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzipora M.","family":"Lustig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osnat","family":"Bohana-Kashtan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ella","family":"Sorani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marya","family":"Chaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaul","family":"Kadosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abi","family":"Vainstein Haras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4723-7681","authenticated-orcid":false,"given":"Daniel D.","family":"Von Hoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3765-3318","authenticated-orcid":false,"given":"Manuel","family":"Hidalgo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,25]]},"reference":[{"key":"880_CR1","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1097\/CJI.0b013e3181eec14c","volume":"33","author":"RE Royal","year":"2010","unstructured":"Royal, R. E. et al. Phase 2 trial of single agent ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J. Immunother. 33, 828\u2013833 (2010).","journal-title":"J. Immunother."},{"key":"880_CR2","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer, J. R. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455\u20132465 (2012).","journal-title":"N. Engl. J. Med."},{"key":"880_CR3","doi-asserted-by":"publisher","first-page":"20212","DOI":"10.1073\/pnas.1320318110","volume":"110","author":"C Feig","year":"2013","unstructured":"Feig, C. et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc. Natl Acad. Sci. USA 110, 20212\u201320217 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"880_CR4","doi-asserted-by":"publisher","first-page":"3934","DOI":"10.1158\/1078-0432.CCR-19-0081","volume":"25","author":"YD Seo","year":"2019","unstructured":"Seo, Y. D. et al. Mobilization of CD8+ T cells via CXCR4 blockade facilitates PD-1 checkpoint therapy in human pancreatic cancer. Clin. Cancer Res. 25, 3934\u20133945 (2019).","journal-title":"Clin. Cancer Res."},{"key":"880_CR5","doi-asserted-by":"publisher","first-page":"3656","DOI":"10.1039\/b306473p","volume":"1","author":"H Tamamura","year":"2003","unstructured":"Tamamura, H. et al. Synthesis of potent CXCR4 inhibitors possessing low cytotoxicity and improved biostability based on T140 derivatives. Org. Biomol. Chem. 1, 3656\u20133662 (2003).","journal-title":"Org. Biomol. Chem."},{"key":"880_CR6","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1158\/0008-5472.CAN-17-0454","volume":"78","author":"S Klein","year":"2018","unstructured":"Klein, S. et al. CXCR4 promotes neuroblastoma growth and therapeutic resistance through miR-15a\/16-1-mediated ERK and BCL2\/cyclin D1 pathways. Cancer Res. 78, 1471\u20131483 (2018).","journal-title":"Cancer Res."},{"key":"880_CR7","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/j.jtcvs.2012.07.031","volume":"144","author":"D Fahham","year":"2012","unstructured":"Fahham, D. et al. In vitro and in vivo therapeutic efficacy of CXCR4 antagonist BKT140 against human non-small cell lung cancer. J. Thorac. Cardiovasc Surg. 144, 1167\u20131175 (2012).","journal-title":"J. Thorac. Cardiovasc Surg."},{"key":"880_CR8","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/S0014-5793(03)00824-X","volume":"550","author":"H Tamamura","year":"2003","unstructured":"Tamamura, H. et al. T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer. FEBS Lett. 550, 79\u201383 (2003).","journal-title":"FEBS Lett."},{"key":"880_CR9","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1200\/JCO.2018.36.5_suppl.73","volume":"36","author":"P Gaur","year":"2018","unstructured":"Gaur, P. et al. CXCR4 antagonist (BL-8040) to enhance antitumor effects by increasing tumor infiltration of antigen-specific effector T-cells. J. Clin. Oncol. 36, 73 (2018).","journal-title":"J. Clin. Oncol."},{"key":"880_CR10","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1038\/leu.2009.56","volume":"23","author":"M Abraham","year":"2009","unstructured":"Abraham, M. et al. The CXCR4 antagonist 4F-benzoyl-TN14003 stimulates the recovery of the bone marrow after transplantation. Leukemia 23, 1378\u20131388 (2009).","journal-title":"Leukemia"},{"key":"880_CR11","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1634\/stemcells.2007-0161","volume":"25","author":"M Abraham","year":"2007","unstructured":"Abraham, M. et al. Enhanced unique pattern of hematopoietic cell mobilization induced by the CXCR4 antagonist 4F-benzoyl-TN14003. Stem Cells 25, 2158\u20132166 (2007).","journal-title":"Stem Cells"},{"key":"880_CR12","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1158\/1078-0432.CCR-13-1302","volume":"20","author":"A Peled","year":"2014","unstructured":"Peled, A. et al. The high-affinity CXCR4 antagonist BKT140 is safe and induces a robust mobilization of human CD34+ cells in patients with multiple myeloma. Clin. Cancer Res. 20, 469\u2013479 (2014).","journal-title":"Clin. Cancer Res."},{"key":"880_CR13","doi-asserted-by":"publisher","first-page":"6790","DOI":"10.1158\/1078-0432.CCR-16-2919","volume":"23","author":"M Abraham","year":"2017","unstructured":"Abraham, M. et al. Single dose of the CXCR4 antagonist BL-8040 induces rapid mobilization for the collection of human CD34+ cells in healthy volunteers. Clin. Cancer Res. 23, 6790\u20136801 (2017).","journal-title":"Clin. Cancer Res."},{"key":"880_CR14","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S0140-6736(15)00986-1","volume":"387","author":"A Wang-Gillam","year":"2016","unstructured":"Wang-Gillam, A. et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet 387, 545\u2013557 (2016).","journal-title":"Lancet"},{"key":"880_CR15","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/cyto.b.21327","volume":"90","author":"M Schwickart","year":"2016","unstructured":"Schwickart, M. et al. Evaluation of assay interference and interpretation of CXCR4 receptor occupancy results in a preclinical study with MEDI3185, a fully human antibody to CXCR4. Cytometry B Clin. Cytom. 90, 209\u2013219 (2016).","journal-title":"Cytometry B Clin. Cytom."},{"key":"880_CR16","doi-asserted-by":"publisher","first-page":"11982","DOI":"10.1073\/pnas.1300136110","volume":"110","author":"MJ Gerdes","year":"2013","unstructured":"Gerdes, M. J. et al. Highly multiplexed single-cell analysis of formalin-fixed, paraffin-embedded cancer tissue. Proc. Natl Acad. Sci. USA 110, 11982\u201311987 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"issue":"Suppl. 1","key":"880_CR17","volume":"7","author":"A Peled","year":"2019","unstructured":"Peled, A. Combination of BL-8040, anti PD-1 and chemotherapy significantly reduced pancreatic tumor growth and changed the balance between CD4+\/FOXP3+ cells and CD8+ cells in the tumor. J. Immunother. Cancer 7 (Suppl. 1), 471 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"880_CR18","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1158\/1078-0432.CCR-17-3099","volume":"24","author":"ZI Hu","year":"2018","unstructured":"Hu, Z. I. et al. Evaluating mismatch repair deficiency in pancreatic adenocarcinoma: challenges and recommendations. Clin. Cancer Res. 24, 1326\u20131336 (2018).","journal-title":"Clin. Cancer Res."},{"key":"880_CR19","unstructured":"Marabelle, A. et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J. Clin. Oncol. 38, 1\u201310 (2019)."},{"key":"880_CR20","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1073\/pnas.1811067116","volume":"116","author":"J Blando","year":"2019","unstructured":"Blando, J. et al. Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer. Proc. Natl Acad. Sci. USA 116, 1692\u20131697 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"880_CR21","doi-asserted-by":"crossref","unstructured":"O\u2019Reilly, E.M. et al. Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial. JAMA Oncol. 5, 1431\u20131438 (2019).","DOI":"10.1001\/jamaoncol.2019.1588"},{"key":"880_CR22","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1038\/onc.2016.273","volume":"36","author":"Y Deng","year":"2017","unstructured":"Deng, Y. et al. Hepatic carcinoma-associated fibroblasts enhance immune suppression by facilitating the generation of myeloid-derived suppressor cells. Oncogene 36, 1090\u20131101 (2017).","journal-title":"Oncogene"},{"key":"880_CR23","first-page":"2022","volume":"39","author":"A Benedicto","year":"2018","unstructured":"Benedicto, A., Romayor, I. & Arteta, B. CXCR4 receptor blockage reduces the contribution of tumor and stromal cells to the metastatic growth in the liver. Oncol. Rep. 39, 2022\u20132030 (2018).","journal-title":"Oncol. Rep."},{"key":"880_CR24","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/nri2216","volume":"8","author":"L Zitvogel","year":"2008","unstructured":"Zitvogel, L., Apetoh, L., Ghiringhelli, F. & Kroemer, G. Immunological aspects of cancer chemotherapy. Nat. Rev. Immunol. 8, 59\u201373 (2008).","journal-title":"Nat. Rev. Immunol."},{"key":"880_CR25","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.4049\/jimmunol.1800275","volume":"201","author":"R Cubas","year":"2018","unstructured":"Cubas, R. et al. Chemotherapy combines effectively with anti-PD-L1 treatment and can augment antitumor responses. J. Immunol. 201, 2273\u20132286 (2018).","journal-title":"J. Immunol."},{"key":"880_CR26","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1093\/jnci\/djx257","volume":"110","author":"JA McKenzie","year":"2018","unstructured":"McKenzie, J. A. et al. The effect of topoisomerase I inhibitors on the efficacy of T-cell-based cancer immunotherapy. J. Natl Cancer Inst. 110, 777\u2013786 (2018).","journal-title":"J. Natl Cancer Inst."},{"key":"880_CR27","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/bjc.2017.376","volume":"118","author":"JS Brown","year":"2018","unstructured":"Brown, J. S., Sundar, R. & Lopez, J. Combining DNA damaging therapeutics with immunotherapy: more haste, less speed. Br. J. Cancer 118, 312\u2013324 (2018).","journal-title":"Br. J. Cancer"},{"key":"880_CR28","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ejca.2018.12.007","volume":"108","author":"A Wang-Gillam","year":"2019","unstructured":"Wang-Gillam, A. et al. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: final overall survival analysis and characteristics of long-term survivors. Eur. J. Cancer 108, 78\u201387 (2019).","journal-title":"Eur. J. Cancer"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41591-020-0880-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41591-020-0880-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41591-020-0880-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T18:03:01Z","timestamp":1684605781000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-020-0880-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,25]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["880"],"URL":"https:\/\/doi.org\/10.1038\/s41591-020-0880-x","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.738011349.793592260","asserted-by":"object"}]},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,25]]},"assertion":[{"value":"30 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.B.: research funding: NanoView Bioscience; travel expenses: Erytech Pharma. T.M.: research funding: Celgene, Beigene and AstraZeneca; consulting: Celgene, BioLineRx, Eisai, Servier, Incyte, AstraZeneca and Amgen; travel expenses: Servier, Merck, Celgene and BioLineRx. B.M.W.: research funding: Celgene and Eli Lilly; consulting: Celgene, G1 Therapeutics, BioLineRx and GRAIL. T.G.: research funding: AstraZeneca and Merck MSD; consultant or advisory role: AstraZeneca, Abbvie, Teva, Bayer and Merck MSD; speakers bureau: Abbvie and BioLineRx. R.G.: consulting or advisory role: Bayer, MSD, Novartis and BOL Pharma; honoraria: BMS, Eli Lilly, Medison, Roche, Novartis, Janssen, Takeda, MSD, Merck and Pfizer; travel expenses: GAD medical, Merck, Roche, BMS and Bayer; educational grant to the research unit: Novartis. J.O.P.: research funding: Celgene; honoraria: Celgene, Sanofi and Servier; consulting or advisory role: Celgene, Sanofi, Servier and Merck Sereno. R.A.R.: research funding: Merck and Aadi Bioscience; consulting or advisory role: Advanced Accelerator Applications, Curium and Novartis; speakers bureau: Merck, Guardant, AstraZeneca, Genentech, Ipsen and Advanced Accelerator Applications. J.F.: research funding: Merck; consulting or advisory role: Amgen, Ipsen, Eisai, Merck, Roche and Novartis; travel expenses: Servier. A.M.: research funding: Sanofi and Leo Pharma; advisory boards: Celgene, AstraZeneca, Roche, Servier, Sanofi, Pfizer, BMS, Leo Pharma, Daiichi Sankyo, Bayer and Halozyme; speakers bureau: Rovi, Eli Lilly and MSD; travel expenses: Celgene, Roche, Merck Serono, Amgen and Sanofi. M.P.-S.: honoraria: Roche and Servier; consulting or advisory role: AstraZeneca; travel expenses: Roche, BMS and Incyte. M.C. is an employee and shareholder of Merck and Co., Inc. T.M.L., O.B.-K., S.M. Shaw, E.S. and A.V.H. are employees of BioLineRx. D.D.V.H.: research funding: Celgene, Merck, FivePrime Therapeutics, Eli Lilly and BioLineRx; consulting or advisory role: FivePrime Therapeutics, Tolero Pharmaceuticals, CanBas, BioLineRx, CytomX, Fujifilm, Geistlich Pharmaceuticals and Ipsen. M.H.: stock and ownership interests: Champions Oncology, Pharmacyte Biotech, BioOncotech, Nelum and Eng T Cell; honoraria: Pfizer, Novartis, MSD Oncology, Celgene, BioLineRx, Champions Oncology, Roche, SOBI, Agenus, Erytech Pharma and Pharmacyte Biotech; consulting or advisory role: Oncomatryx Biopharma S.L., Novartis, Pfizer, Celgene, Merck, Champions Oncology, Pharmacyte Biotech, SOBI, Roche, BioLineRx, Erytech Pharma, Agenus, Bayer, BMS, Nelum and Eng T Cells; research funding: Berg, Oncomatryx Biopharma S.L., Pfizer, Celgene, Bicycle Therapeutics, BioLineRx and Asana Biosciences; patents, royalties and other intellectual property: Myriad Genetics. The remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}